相关实验视频
Updated: Jun 21, 2025

08:50
Establishment and Evaluation of a Porcine Vein Graft Disease Model
Published on: July 25, 2022
1.7K
凝血异常和血管并发症在PGM1-CDGG中很常见
Silvia Radenkovic1, Sofie Bleukx2, Nicole Engelhardt3
1Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA; Department of Genetics, Section Metabolic Diagnostics, UMC Utrecht, Utrecht, NL.
Molecular genetics and metabolism
|July 5, 2024
概括
凝血异常常见于糖突变酶-1-血糖化 (PGM1-CDG) 的先天性障碍,并且在治疗D-银糖时得到改善. 抗血素缺乏症很常见,而D-银糖在治疗这些PGM1-CDG并发症方面表现有前途.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
背景情况:
- 糖突变酶-1-先天性糖化乱 (PGM1-CDG) 是一种罕见的遗传性疾病,影响PGM1酶.
- 临床特征包括肌肉,心脏和生长问题,以及肝脏和凝血异常.
- 在PGM1-CDG中的凝血缺陷的程度和治疗仍然不太清楚.
研究的目的:
- 确定PGM1-CDG患者凝血异常的发生率和演变.
- 调查凝血问题与临床事件之间的关系.
- 评估D-银糖 (D-gal) 补充剂在改善凝血参数方面的疗效.
主要方法:
- 对73名具有分子确认诊断的PGM1-CDG患者的回顾性分析.
- 收集凝血数据 (抗凝血素,aPTT,PT等) 和临床事件.
- 来自FCDGC自然史研究的纵向数据对16名额外患者的评估.
主要成果:
- 有可用数据的67.4%的个人报告了凝血异常,最常见的是抗血素 (AT) 缺乏 (平均30.8%).
- 四名患者经历了主要的血栓事件.
- 在接受治疗的患者中,D-银糖治疗导致了AT水平 (平均64.5%) 和其他参数的显著改善.
结论:
- 凝血异常是PGM1-CDG的常见并发症.
- 补充D-银糖对PGM1-CDG的凝血参数产生有益影响.
- 建议定期监测凝血参数和AT水平,作为临床试验的临床终点.
相关概念视频
Disorders of Hemostasis
824
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
824
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
Formation of the Platelet Plug
5.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.7K

